syl040012
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00990743)
Timeline
Indications
Mechanism of action
- Beta-2 adrenergic receptorANTISENSE INHIBITOR
ADRB2 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- syl040012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01739244 | Phase 2 | Jul 1, 2012 | PharmaMar |
| NCT01227291 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Clinica Universidad de Navarra, PharmaMar, Universidad Complutense de Madrid |
| NCT00990743 | Phase 1 | Sep 1, 2009 | PharmaMar |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PharmaMar | For profit | 3 | 3 | 2 | 2009 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1